Barcelona, Spain-basedAlmirall has formed a research alliance with BioFocus, an affiliate of Galapagos. The three-year collaboration is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. 

“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies” said Dr. Bertil Lindmark, CSO, executive director of R&D at Almirall.

BioFocus will apply its integrated drug discovery capabilities while Almirall will bring its respiratory-specific knowledge to the joint experimental effort. The value of the collaboration with BioFocus could reach roughly $9.8 million.